Compare Five Below Inc (FIVE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Tango Therapeutics Inc. — how do they compare? Five Below Inc trades at $218.95 (market cap $11.75B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Five Below Inc is far larger — about 3.1× Tango Therapeutics Inc.'s market cap, and Five Below Inc is more actively traded (742,657 versus 9,619,106). Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Tango Therapeutics Inc. for 0 Days on average.
| FIVE | TNGX | |
|---|---|---|
Market Cap | $11.75B | $3.75B |
Volume | 742,657 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $32.90 |
52-Week Low | $147.05 | $7.50 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $12.60B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $218.95, up 2.51% today, with strong earnings momentum after beating Q1 and Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600M buyback and digital marketing push. Revenue growth accelerated from $3.6B in 2024 to $3.9B in 2025, with projected $5.3B in 2026.
FIVE presents a growth opportunity with analyst consensus target of $298.44 (36% upside), though execution risks remain. The premium valuation (P/E 19.14) requires sustained margin expansion amid consumer spending pressures. Institutional sentiment is bullish with 60% buy ratings, but technical weakness near resistance at $219 suggests near-term consolidation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
